<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614129</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002693</org_study_id>
    <nct_id>NCT04614129</nct_id>
  </id_info>
  <brief_title>Lung Cancer Risk and Early Detection in Firefighters</brief_title>
  <official_title>Lung Cancer Risk and Early Detection in Firefighters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether LDCT findings differ between firefighters and non-fighters,&#xD;
      the relationship between occupational exposures and LDCT findings, and whether a proteomics&#xD;
      assay can further risk-stratify screen-detected nodules among a study population of 420&#xD;
      current and retired firefighters and 1680 matched controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nodule detection rate</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of nodule detection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-risk nodule detection rate</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of high-risk nodule detection. High risk is defined as a Lung RADS of 3 or 4. Lung RADS categories are as follows: 0) Incomplete; 1) Negative; 2) Benign appearance or behavior; 3) Probably benign; 4) Suspicious</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial lung disease detection rate</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of interstitial lung disease detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery calcification (CAC) ordinal scores</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of high coronary artery calcification (CAC) ordinal scores. Possible scores range from 0 to 12 and high scores are defined as those greater than or equal to 10</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Low-Dose CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose CT Scan of the Chest</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Low Dose CT</intervention_name>
    <description>All participants will have a low dose chest CT either within one year of enrollment or after enrollment</description>
    <arm_group_label>Low-Dose CT</arm_group_label>
    <other_name>LDCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40-70 years of age or with 10 years of firefighting experience&#xD;
&#xD;
          -  Current or retired firefighters in the Boston/Greater Boston area&#xD;
&#xD;
          -  No personal history of lung cancer&#xD;
&#xD;
          -  Willing and able to receive LDCT screening at MGH or who have been screened via LDCT&#xD;
             within the past year at MGH or another institution, and are willing to release their&#xD;
             images to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active cancer (undergoing treatment or diagnosed within the past 5 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica T Warner, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lecia V Sequist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Administrator</last_name>
    <phone>6177249516</phone>
    <email>mghfhs@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Administrator</last_name>
      <email>mghfhs@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Erica T. Warner</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

